NLRP3 and Salla disease: Pretreatment of a non-specific ROS scavenger, PBN, by intrathecal administration, effectively alleviated SD-associated pathological development through enhancing PWMT and PWTL, inhibiting microglia activation and suppressing ROS levels via the NF-κB/NLRP3 signaling pathway.